Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus

Journal of Infectious Diseases

Volumn 211, Issue 12, 2015, Pages 1862-1874

  Rose, Hannah R ^a   Holzman, Robert S ^a   Altman, Deena R ^c   Smyth, Davida S ^a   Wasserman, Gregory A ^a,f   Kafer, Jared M ^a   Wible, Michelle ^d   Mendes, Rodrigo E ^e   Torres, Victor J ^b   Shopsin, Bo ^a  

^a New York School of Medicine   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e JMI LABORATORIES   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MRSA; nosocomial pneumonia; outcome; Staphylococcus aureus; virulence

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CULTURE MEDIUM; VIRULENCE FACTOR;

ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CORRELATIONAL STUDY; CYTOTOXICITY; DEATH; DISEASE SEVERITY; FEMALE; FRAIL ELDERLY; GENOTYPE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ADOLESCENT; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CROSS INFECTION; CULTURE MEDIUM; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; NEUTROPHIL; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL PNEUMONIA; TOXICITY; VERY ELDERLY; VIRULENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CELL LINE; CELL SURVIVAL; CROSS INFECTION; CULTURE MEDIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NEUTROPHILS; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN; VIRULENCE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84930363665     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu554     Document Type: Article

References (49)

1. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-7.
2. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150: 1545-9.
3. Rubinstein E, KollefMH, Nathwani D. Pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Infect Dis 2008; 46(suppl 5): S378-85.
4. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-7.
5. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41:583-90.
6. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894-9.
7. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84.
8. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647-56.
9. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008; 46:787-94.
10. Chen SY, Liao CH, Wang JL, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis 2012; 55:1329-37.
11. Lalani T, Federspiel JJ, Boucher HW, et al. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol 2008; 46:2890-6.
12. Sharma-Kuinkel BK, Ahn SH, Rude TH, et al. Presence of genes encoding Panton-Valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol 2012; 50:848-56.
13. Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1165-72.
14. Luna CM, Niederman MS. What is the natural history of resolution of nosocomial pneumonia? Semin Respir Crit Care Med 2002; 23:471-9.
15. Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev of Respir Dis 1990; 142:523-8.
16. Bregeon F, Ciais V, Carret V, et al. Is ventilator-associated pneumonia an independent risk factor for death? Anesthesiology 2001; 94:554-60.
17. Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154:91-7.
18. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
19. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia. J Clin Microbiol 2012; 50:3694-702.
20. Smyth DS, Kafer JM, Wasserman GA, et al. Nasal Carriage as a Source of agr-Defective Staphylococcus aureus Bacteremia. J Infect Dis 2012; 206:1168-77.
21. Cheung GY, Duong AC, Otto M. Direct and synergistic hemolysis caused by Staphylococcus phenol-soluble modulins: implications for diagnosis and pathogenesis. Microbes Infect 2012; 14:380-6.
22. Elek SD, Levy E. Distribution of haemolysins in pathogenic and nonpathogenic staphylococci. J Pathol Bacteriol 1950; 62:541-54.
23. Shopsin B, Eaton C,Wasserman GA, et al. Mutations in agr do not persist in natural populations of methicillin-resistant Staphylococcus aureus. J Infect Dis 2010; 202:1593-9.
24. Traber KE, Lee E, Benson S, et al. agr function in clinical Staphylococcus aureus isolates. Microbiology 2008; 154:2265-74.
25. Vuong C, Kocianova S, Yao Y, Carmody AB, Otto M. Increased colonization of indwelling medical devices by quorum-sensing mutants of Staphylococcus epidermidis in vivo. J Infect Dis 2004; 190:1498-505.
26. DuMont AL, Yoong P, Day CJ, et al. Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc Natl Acad Sci U S A 2013; 110:10794-9.
27. Dumont AL, Nygaard TK, Watkins RL, et al. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol 2011; 79:814-25.
28. Morinaga N, NagamoriM, Kato I. Changes in binding of staphylococcal leukocidin to HL-60 cells during differentiation induced by dimethyl sulfoxide. Infect Immun 1988; 56:2479-83.
29. Li M, Du X, Villaruz AE, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med 2012; 18:816-9.
30. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48:1429-49.
31. Alonzo F III, Torres VJ. Bacterial survival amidst an immune onslaught: the contribution of the Staphylococcus aureus leukotoxins. PLoS Pathog 2013; 9:e1003143.
32. Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bicomponent leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front Cell Infect Microbiol 2012; 2:12.
33. Cheung GY, Joo HS, Chatterjee SS, Otto M. Phenol-soluble modulins-critical determinants of staphylococcal virulence. FEMS Microbiol Rev 2014; 38:698-719.
34. van Hal SJ, Fowler VG Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 2013; 56:1779-88.
35. Sakoulas G. The accessory gene regulator (agr) in methicillin-resistant Staphylococcus aureus: role in virulence and reduced susceptibility to glycopeptide antibiotics. Drug Discov Today 2006; 3:287-94.
36. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-502.
37. Cameron DR, Ward DV, Kostoulias X, et al. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis 2012; 205: 1677-87.
38. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009; 199:532-6.
39. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Communityassociated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557-68.
40. Bae IG, Tonthat GT, Stryjewski ME, et al. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol 2009; 47:3952-7.
41. Peyrani P, Allen M, Seligson D, et al. Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains. Am J Orthop (Belle Mead NJ) 2012; 41:117-22.
42. Malachowa N, Kobayashi SD, Braughton KR, et al. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis 2012; 206:1185-93.
43. Malachowa N, Kobayashi SD, Freedman B, Dorward DW, DeLeo FR. Staphylococcus aureus leukotoxin GH promotes formation of neutrophil extracellular traps. J Immunol 2013; 191:6022-9.
44. Yoong P, Pier GB. Immune-activating properties of Panton-Valentine leukocidin improve the outcome in a model of methicillin-resistant Staphylococcus aureus pneumonia. Infect Immun 2012; 80:2894-904.
45. Li M, Cheung GY, Hu J, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 2010; 202:1866-76.
46. Voyich JM, Braughton KR, Sturdevant DE, et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005; 175:3907-19.
47. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13:1510-4.
48. Robinson DA, Enright MC. Evolution of Staphylococcus aureus by large chromosomal replacements. J Bacteriol 2004; 186:1060-4.
49. Fowler VG Jr, Nelson CL, McIntyre LM, et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007; 196:738-47.